Group 1 - The core viewpoint emphasizes that technological innovation is the driving force for high-quality development, with a focus on original innovation and breakthroughs in key core technologies in the biopharmaceutical sector [1] - The approval of the world's first GCG/GLP-1 dual-target weight loss and blood sugar-lowering drug, developed by Innovent Biologics, marks a significant achievement in original drug development [1] - Innovent Biologics has successfully developed 18 innovative drugs since its establishment in 2011, with 12 included in the national medical insurance directory, benefiting over 6 million patients [2][3] Group 2 - The approval of the first new drug for thyroid eye disease in 70 years fills a significant gap in domestic treatment options, providing new choices for patients [2] - The launch of the first domestically developed IL-23p19 monoclonal antibody by a local company demonstrates ongoing efforts in niche therapeutic areas [2] - Innovent Biologics has invested a total of 30 billion yuan in research and development, establishing three major R&D centers in Shanghai, Suzhou, and the United States, with over 2,000 researchers [3]
信达生物：从“全球首个”到填补70年空白，以原始创新抢占生物医药科技制高点